Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:56:18.677Z.
Consensus retrieved: 2026-10-06T10:08:12.590Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:56:18.677Z.
Quote observation: 2026-10-06T14:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6224f8b57f7cae82e1059df5c2bb45f5346f18e23f52b02bfc982dc52e16f10
Forward PE Ratio (N/A) = Dated Quote Price ($2.27) / Consensus Forward EPS ($-0.28)
FORWARD PE RATIO
N/A
Compugen Ltd.
Market Cap
$214.16M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Compugen Ltd. (CGEN) | $214.16M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.79M | 18.70 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $213.31M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $215.57M | N/A |
| Alector, Inc. (ALEC)vs › | $211.50M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $224.05M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $203.43M | N/A |
| Biodesix, Inc. (BDSX)vs › | $225.53M | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | N/A |
| BioAge Labs Inc. (BIOA)vs › | $234.93M | N/A |
Trailing P/E
6.0
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.27, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.28 | $-0.35 – $-0.19 | 3 | n/m |
| 2027-12-31 | $-0.28 | $-0.57 – $0.15 | 3 | n/m |
| 2028-12-31 | $-0.25 | $-0.26 – $-0.25 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
